Table 1.
The characteristics of non-small-cell lung cancer patients enrolled
| Characteristics | N=134 (%) |
|---|---|
| Gender | |
| Male | 101 (75.3) |
| Female | 33 (24.7) |
| Age (years) | 62.6±10.1 |
| Histological subtype | |
| Small cell | 25 (18.7) |
| Squamous carcinoma | 54 (40.3) |
| Adenocarcinoma | 46 (34.3) |
| Others | 9 (6.7) |
| Tumor location | 43 (32.1) |
| Left upper lobe | 12 (9.0) |
| Left lower lobe | 55 (41.0) |
| Right upper lobe | 24 (17.9) |
| Right lower lobe | |
| Stage | |
| 1 | 12 (9.0) |
| 2 | 6 (4.5) |
| 3 | 63 (47.0) |
| 4 | 53 (39.5) |
| Chemotherapy | |
| Yes | 110 (82.1) |
| No | 24 (17.9) |
| Average dose Prescription (Gy) | 57.07±6.27 |
| Lung dosimetry | |
| V5 (%) | 59.9±18.2 |
| V10 (%) | 44.6±16.0 |
| V13 (%) | 36.9±13.3 |
| V20 (%) | 24.6±8.5 |
| V30 (%) | 16.0±5.3 |
| Mean dose (Gy) | 15.08±3.31 |
| Heart dosimetry | |
| V25 (%) | 25.8±17.4 |
| V30 (%) | 20.8±14.2 |
| V50 (%) | 6.8±6.9 |
| Mean dose (Gy) | 15.20±8.61 |
| PTV parameters | |
| Volume (cm3) | 408.2±325.1 |
| Mean dose (Gy) | 54.91±9.57 |
| Max dose (Gy) | 60.61±8.69 |